Opioid antagonists such as naloxone can precipitate abstinence signs and symptoms when administered several hours after acute exposure to a short- acting opioid agonist drug. This observation is rather remarkable since abstinence signs are generally associated with chronic exposure to opioid drugs, where they denote the presence of physical dependence. The antagonist precipitated withdrawal signs seen after brief exposure to opioid agonist drug (antagonist sensitivity) may represent the incipient stages of opioid physical dependence. The human pharmacology of opioid antagonist sensitivity is the focus of the present grant project. By examining the pharmacology of antagonist sensitivity, we hope to understand its relationship to development of opioid physical dependence in man. In the present application, our first priority is to complete dose-effect and time course studies to bring this aspect of the project to closure. Our next priority is to establish pharmacological specificity in relation to the physical dependence profile of pretreatment drugs. A third priority, which can be pursued concurrently with other studies, is to explore opiate exposure history of the subject as a potential determinant of individual differences in the antagonist sensitivity response. Specific studies proposed will examine high dose naloxone effects and morphine/naloxone dose interactions in order to clarify interpretation of precipitated abstinence effects (Exp. 1), examine in a single study the full time course of antagonist sensitivity effects from 1 to 36 hours after acute opioid exposure (Exp 2), examine precipitated abstinence intensity as a function of antagonist challenge procedures, particularly the route and speed of antagonist drug administration (Exp 3), examine the intensity and duration of precipitated abstinence effects following pretreatment with several short-acting opioid agonists, mixed agonist-antagonists, and nonopioid drugs (Exps. 6,7), examine the influence of opioid duration of action and receptor occupancy characteristics by comparing precipitated abstinence effects following pretreatment with mu agonists that differ widely on these dimensions including fentanyl, morphine, methadone, buprenorphine (Exps 8 - 10), examine agonist pretreatment and antagonist challenge parameters that influence precipitated abstinence effects in subject lacking opioid exposure histories (Exps. 11 - 14) and finally examine in a prospective study the influence of opioid exposure history (opioid naive versus opioid experienced) on precipitated abstinence responses following brief opioid exposure (Exp 15).Overall, these studies will improve our understanding of acute antagonist sensitivity while clarifying its relationship to the pharmacology/physical dependence profile of opioid and nonopioid drugs and to the development of chronic opioid physical dependence in human.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA004011-09
Application #
2116926
Study Section
Drug Abuse Clinical and Behavioral Research Review Committee (DACB)
Project Start
1986-04-01
Project End
1995-05-31
Budget Start
1994-04-01
Budget End
1995-05-31
Support Year
9
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Becker, A B; Strain, E C; Bigelow, G E et al. (2001) Gradual dose taper following chronic buprenorphine. Am J Addict 10:111-21
Schuh, K J; Walsh, S L; Stitzer, M L (1999) Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (Berl) 145:162-74
Eissenberg, T; Stitzer, M L; Bigelow, G E et al. (1999) Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions. J Pharmacol Exp Ther 289:936-45
Greenwald, M K; Stitzer, M L (1998) Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine. Drug Alcohol Depend 53:17-30
Eissenberg, T; Johnson, R E; Bigelow, G E et al. (1997) Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend 45:81-91
Greenwald, M K; Stitzer, M L; Haberny, K A (1997) Human pharmacology of the opioid neuropeptide dynorphin A(1-13). J Pharmacol Exp Ther 281:1154-63
Greenwald, M K; June, H L; Stitzer, M L et al. (1996) Comparative clinical pharmacology of short-acting mu opioids in drug abusers. J Pharmacol Exp Ther 277:1228-36
Schuh, K J; Walsh, S L; Bigelow, G E et al. (1996) Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J Pharmacol Exp Ther 278:836-46
Eissenberg, T; Greenwald, M K; Johnson, R E et al. (1996) Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 276:449-59
June, H L; Stitzer, M L; Cone, E (1995) Acute physical dependence: time course and relation to human plasma morphine concentrations. Clin Pharmacol Ther 57:270-80

Showing the most recent 10 out of 20 publications